Tags

Type your tag names separated by a space and hit enter

A short-term n-3 DPA supplementation study in humans.
Eur J Nutr. 2013 Apr; 52(3):895-904.EJ

Abstract

PURPOSE

Despite the detailed knowledge of the absorption and incorporation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) into plasma lipids and red blood cells (RBC) in humans, very little is known about docosapentaenoic acid (DPA, 22:5 n-3). The aim of this study was to investigate the uptake and incorporation of pure DPA and EPA into human plasma and RBC lipids.

METHODS

Ten female participants received 8 g of pure DPA or pure EPA in randomized crossover double-blinded manner over a 7-day period. The placebo treatment was olive oil. Blood samples were collected at days zero, four and seven, following which the plasma and RBC were separated and used for the analysis of fatty acids.

RESULTS

Supplementation with DPA significantly increased the proportions of DPA in the plasma phospholipids (PL) (by twofold) and triacylglycerol (TAG) fractions (by 2.3-fold, day 4). DPA supplementation also significantly increased the proportions of EPA in TAG (by 3.1-fold, day 4) and cholesterol ester (CE) fractions (by 2.0-fold, day 7) and of DHA in TAG fraction (by 3.1-fold, day 4). DPA proportions in RBC PL did not change following supplementation. Supplementation with EPA significantly increased the proportion of EPA in the plasma CE and PL fractions, (both by 2.7-fold, day 4 and day 7) and in the RBC PL (by 1.9-fold, day 4 and day 7). EPA supplementation did not alter the proportions of DPA or DHA in any lipid fraction. These results showed that within day 4 of supplementation, DPA and EPA demonstrated different and specific incorporation patterns.

CONCLUSION

The results of this short-term study suggest that DPA may act as a reservoir of the major long-chain n-3 fatty acids (LC n-3 PUFA) in humans.

Authors+Show Affiliations

School of Exercise and Nutrition Sciences, Deakin University, Burwood, VIC, 3126, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22729967

Citation

Miller, Eliza, et al. "A Short-term N-3 DPA Supplementation Study in Humans." European Journal of Nutrition, vol. 52, no. 3, 2013, pp. 895-904.
Miller E, Kaur G, Larsen A, et al. A short-term n-3 DPA supplementation study in humans. Eur J Nutr. 2013;52(3):895-904.
Miller, E., Kaur, G., Larsen, A., Loh, S. P., Linderborg, K., Weisinger, H. S., Turchini, G. M., Cameron-Smith, D., & Sinclair, A. J. (2013). A short-term n-3 DPA supplementation study in humans. European Journal of Nutrition, 52(3), 895-904. https://doi.org/10.1007/s00394-012-0396-3
Miller E, et al. A Short-term N-3 DPA Supplementation Study in Humans. Eur J Nutr. 2013;52(3):895-904. PubMed PMID: 22729967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A short-term n-3 DPA supplementation study in humans. AU - Miller,Eliza, AU - Kaur,Gunveen, AU - Larsen,Amy, AU - Loh,Su Peng, AU - Linderborg,Kaisa, AU - Weisinger,Harrison S, AU - Turchini,Giovanni M, AU - Cameron-Smith,David, AU - Sinclair,Andrew J, Y1 - 2012/06/23/ PY - 2012/03/04/received PY - 2012/05/30/accepted PY - 2012/6/26/entrez PY - 2012/6/26/pubmed PY - 2013/10/22/medline SP - 895 EP - 904 JF - European journal of nutrition JO - Eur J Nutr VL - 52 IS - 3 N2 - PURPOSE: Despite the detailed knowledge of the absorption and incorporation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) into plasma lipids and red blood cells (RBC) in humans, very little is known about docosapentaenoic acid (DPA, 22:5 n-3). The aim of this study was to investigate the uptake and incorporation of pure DPA and EPA into human plasma and RBC lipids. METHODS: Ten female participants received 8 g of pure DPA or pure EPA in randomized crossover double-blinded manner over a 7-day period. The placebo treatment was olive oil. Blood samples were collected at days zero, four and seven, following which the plasma and RBC were separated and used for the analysis of fatty acids. RESULTS: Supplementation with DPA significantly increased the proportions of DPA in the plasma phospholipids (PL) (by twofold) and triacylglycerol (TAG) fractions (by 2.3-fold, day 4). DPA supplementation also significantly increased the proportions of EPA in TAG (by 3.1-fold, day 4) and cholesterol ester (CE) fractions (by 2.0-fold, day 7) and of DHA in TAG fraction (by 3.1-fold, day 4). DPA proportions in RBC PL did not change following supplementation. Supplementation with EPA significantly increased the proportion of EPA in the plasma CE and PL fractions, (both by 2.7-fold, day 4 and day 7) and in the RBC PL (by 1.9-fold, day 4 and day 7). EPA supplementation did not alter the proportions of DPA or DHA in any lipid fraction. These results showed that within day 4 of supplementation, DPA and EPA demonstrated different and specific incorporation patterns. CONCLUSION: The results of this short-term study suggest that DPA may act as a reservoir of the major long-chain n-3 fatty acids (LC n-3 PUFA) in humans. SN - 1436-6215 UR - https://www.unboundmedicine.com/medline/citation/22729967/A_short_term_n_3_DPA_supplementation_study_in_humans_ L2 - https://dx.doi.org/10.1007/s00394-012-0396-3 DB - PRIME DP - Unbound Medicine ER -